US-based Gilead has entered into a ten-year global research and development (R&D) collaboration agreement with Belgian clinical stage biotech Galapagos, in which the former will pay $3.95bn upfront to again...
15 July 2019 Analysis
11 July 2019 Comment
PNH is a very rare blood disorder with limited treatment options. Ultomiris is only the second drug to be approved for this indication, after Alexion’s Soliris (eculizumab) was approved in...
9 July 2019 Comment
Key opinion leaders interviewed by GlobalData are highly optimistic about ACP therapies and agree that they will drive change in the treatment landscapes for haemophilia A and B.
5 July 2019 Comment
The immune system is a well-characterised mediator of both common and rare neurological conditions.
2 July 2019 Comment
US regulator issues a safety warning about the use of faecal microbiota transplantation (FMT) for the treatment of C. difficile.
19 June 2019 Comment
According to the British Skin Foundation, hidradenitis suppurativa is a long term, recurrent and painful disease in which there is inflammation (redness, tenderness and swelling) in areas of skin containing...
17 June 2019 News
Johnson & Johnson subsidiary Janssen has announced that Tremfya (guselkumab) reached its primary endpoint in the Phase III DISCOVER one and two studies, where it is being investigated for adults...
10 June 2019 Analysis
Diabetes UK use its annual Diabetes Week to raise awareness, as well as funds for, among other things, crucial research into new treatments for diabetes. One largely neglected therapeutic approach...
31 May 2019 Comment
The goal of maternal immunisation is to induce a de novo antibody response in the pregnant mother that can then be transmitted to the infant through the placenta.